WDNA WisdomTree BioRevolution Fund
Kuotasi per Aug 26, 2026 18:26 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Penutupan Sebelumnya | 24.07 | Rentang Harian | 23.75 – 23.98 |
| Kisaran 52 Minggu | 14.14 – 24.20 | Volume | 20.90K |
| Volume Rata-Rata | 1.48K | AUM | $3.1M (Aug 27, 2026) |
| Expense Ratio | 0.45% | Yield (TTM) | 3.22% |
| NAV | 23.62 | Premium/Diskon | +1.19% indikatif |
| Inception | Jun 03, 2021 | Kepemilikan | 99 |
| Penerbit | WisdomTree | Bursa | CBOE |
| Kategori | Healthcare | Indeks yang Dilacak | Tidak tercantum dalam data sumber |
| CUSIP | 97717Y618 | ISIN | US97717Y6187 |
| Manajemen | Tidak tercantum dalam data sumber | ||
Tentang ETF ini
This fund primarily aims to meet its investment goals by employing a representative sampling method. This means it selects a portion of the securities from its benchmark index, ensuring that this smaller selection closely reflects the broader index's risk profile, expected returns, and other key characteristics. The benchmark index itself is crafted to invest in global, exchange-listed companies that are poised for significant transformation through breakthroughs in genetic research and biotechnology. It's important to note that this fund is categorized as non-diversified.
Deskripsi dari penyedia data dana · profil per Aug 27, 2026.
Grafik Harga
Harga penutupan harian (imbal hasil harga, bukan imbal hasil total). Garis perbandingan dinormalisasi ke perubahan persentase dari awal rentang waktu. Sumber: Financial Modeling Prep.
Kinerja
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Return harga | +21.38% | +32.70% | +30.17% | +41.59% | +66.32% | +13.57% | -2.56% | — | -0.84% |
| Total return | +21.38% | +32.70% | +30.17% | +41.59% | +73.69% | +15.81% | -1.30% | — | +0.37% |
* Disetahunkan. Total imbal hasil menggunakan seri harga yang disesuaikan dengan dividen (distribusi diinvestasikan kembali); imbal hasil harga menggunakan harga penutupan tanpa penyesuaian. Kinerja hingga Aug 26, 2026. Kinerja masa lalu tidak menjamin hasil di masa depan.
Biaya
| Expense ratio bersih | 0.45% | Biaya tahunan untuk investasi $10.000 | $45.00 |
Hanya kalkulasi ilustrasi: expense ratio × $10.000. Tidak termasuk biaya perdagangan, selisih bid/ask, pajak, dan perubahan nilai investasi. Detail expense ratio bruto vs. neto dan setiap pengabaian biaya tersedia dalam prospektus.
Kepemilikan
Kepemilikan per May 15, 2026 — tanggal pelaporan portofolio dari penyedia data; kepemilikan bukan posisi langsung. 87 baris dalam basis data.
| # | Kepemilikan | Ticker | Bobot | Saham | Nilai Pasar |
|---|---|---|---|---|---|
| 1 | Eli Lilly & Co | LLY | 3.98% | 91 | $91.6K |
| 2 | Twist Bioscience Corp | TWST | 3.56% | 1.55K | $82.0K |
| 3 | Moderna Inc | MRNA | 3.44% | 1.58K | $79.2K |
| 4 | Johnson & Johnson | JNJ | 3.14% | 313 | $72.2K |
| 5 | United Therapeutics Corp | UTHR | 3.03% | 121 | $69.7K |
| 6 | Immunome Inc | IMNM | 2.73% | 2.85K | $62.8K |
| 7 | Darling Ingredients Inc | DAR | 2.59% | 949 | $59.6K |
| 8 | Stoke Therapeutics Inc | STOK | 2.33% | 1.71K | $53.7K |
| 9 | Corteva Inc | CTVA | 2.28% | 629 | $52.4K |
| 10 | Beam Therapeutics Inc | BEAM | 2.09% | 1.63K | $48.1K |
| 11 | Tempus Ai Inc | TEM | 2.08% | 1.05K | $48.0K |
| 12 | ASTRAZENECA PLC | AZN | 2.07% | 258 | $47.7K |
| 13 | Isis Pharmaceuticals Inc | ISIS | 2.06% | 627 | $47.5K |
| 14 | Bunge Global Sa | 2318605D | 2.02% | 378 | $46.6K |
| 15 | Natera Inc | NTRA | 1.96% | 229 | $45.1K |
| 16 | Krystal Biotech Inc | KRYS | 1.94% | 141 | $44.6K |
| 17 | Crispr Therapeutics Ag | CRSP | 1.90% | 868 | $43.8K |
| 18 | Gilead Sciences Inc | GILD | 1.84% | 320 | $42.3K |
| 19 | Structure Therapeutics Inc | GPCR | 1.83% | 1.05K | $42.0K |
| 20 | Roivant Sciences Ltd | ROIV | 1.68% | 1.31K | $38.6K |
| 21 | Arrowhead Pharmaceuticals Inc | ARWR | 1.68% | 484 | $38.6K |
| 22 | Pfizer Inc | PFE | 1.67% | 1.49K | $38.5K |
| 23 | Amgen Inc | AMGN | 1.66% | 114 | $38.3K |
| 24 | Thermo Fisher Scientific Inc | TMO | 1.58% | 81 | $36.3K |
| 25 | Revolution Medicines Inc | RVMD | 1.56% | 241 | $36.0K |
| 26 | Novozymes A/S | NZYM-B.CO | 1.49% | 582 | $34.4K |
| 27 | Novartis AG | NOVN.SW | 1.47% | 227 | $33.9K |
| 28 | Bayer AG | BAYN.DE | 1.44% | 741 | $33.0K |
| 29 | Agios Pharmaceuticals Inc | AGIO | 1.41% | 1.13K | $32.6K |
| 30 | Vertex Pharmaceuticals Inc | VRTX | 1.41% | 72 | $32.4K |
| 31 | Catalyst Pharmaceuticals Inc | CPRX | 1.24% | 914 | $28.5K |
| 32 | 10X Genomics Inc-Class A | TXG | 1.18% | 1.26K | $27.2K |
| 33 | Exelixis Inc | EXEL | 1.14% | 514 | $26.3K |
| 34 | Veracyte Inc | VCYT | 1.13% | 666 | $25.9K |
| 35 | Verbio AG | VBK.DE | 1.10% | 520 | $25.3K |
| 36 | Cullinan Therapeutics Inc | CGEM | 1.07% | 1.53K | $24.7K |
| 37 | Protagonist Therapeutics Inc | PTGX | 1.03% | 224 | $23.6K |
| 38 | Cg Oncology Inc | CGON | 1.03% | 340 | $23.6K |
| 39 | Biontech Se-ADR | BNTX | 1.01% | 252 | $23.2K |
| 40 | Allogene Therapeutics Inc | ALLO | 0.98% | 10.53K | $22.5K |
| 41 | Celldex Therapeutics Inc | CLDX | 0.98% | 694 | $22.5K |
| 42 | Editas Medicine Inc | EDIT | 0.98% | 7.88K | $22.5K |
| 43 | Biohaven Ltd | BHVN | 0.97% | 2.47K | $22.3K |
| 44 | Argenx Se - Adr | ARGX | 0.96% | 27 | $22.2K |
| 45 | Dyne Therapeutics Inc | DYN | 0.96% | 1.21K | $22.0K |
| 46 | ABSCI Corp | ABSI | 0.95% | 3.94K | $21.8K |
| 47 | Viking Therapeutics Inc | VKTX | 0.88% | 639 | $20.3K |
| 48 | Uniqure NV | QURE | 0.86% | 713 | $19.8K |
| 49 | Biogen Idec Inc | BIIB | 0.85% | 102 | $19.5K |
| 50 | FMC Corp | FMC | 0.80% | 1.36K | $18.4K |
| 51 | Iovance Biotherapeutics Inc | IOVA | 0.76% | 4.94K | $17.4K |
| 52 | Danaher Corp | DHR | 0.75% | 105 | $17.3K |
| 53 | Arcturus Therapeutics Hlgs | ARCT | 0.74% | 2.19K | $17.1K |
| 54 | Insmed Inc | INSM | 0.73% | 146 | $16.9K |
| 55 | Green Plains Inc | GPRE | 0.73% | 1.01K | $16.8K |
| 56 | Merck & Co Inc/NJ | MRK | 0.72% | 146 | $16.6K |
| 57 | Regeneron Pharmaceuticals Inc | REGN | 0.71% | 23 | $16.4K |
| 58 | Sana Biotechnology Inc | SANA | 0.70% | 5.16K | $16.2K |
| 59 | Halozyme Therapeutics Inc | HALO | 0.67% | 222 | $15.4K |
| 60 | Syensqo Sa | SYENS.BR | 0.64% | 214 | $14.7K |
| 61 | Repligen Corp | RGEN | 0.64% | 142 | $14.7K |
| 62 | Regenxbio Inc | RGNX | 0.56% | 2.08K | $13.0K |
| 63 | Ultragenyx Pharmaceutical Inc | RARE | 0.54% | 479 | $12.4K |
| 64 | Nufarm Ltd/Australia | NUF.AX | 0.53% | 7.10K | $12.2K |
| 65 | Bridgebio Pharma Inc | BBIO | 0.52% | 172 | $12.0K |
| 66 | Illumina Inc | ILMN | 0.51% | 82 | $11.7K |
| 67 | Intellia Therapeutics Inc | NTLA | 0.48% | 841 | $11.0K |
| 68 | Genmab A/S -Sp ADR | GMAB | 0.48% | 408 | $11.0K |
| 69 | BioMarin Pharmaceutical Inc | BMRN | 0.47% | 204 | $10.9K |
| 70 | Oxford Nanopore Technologies | ONT.L | 0.47% | 6.50K | $10.8K |
| 71 | Genus Plc | GNS.L | 0.44% | 320 | $10.2K |
| 72 | Zoetis Inc | ZTS | 0.44% | 135 | $10.2K |
| 73 | Geron Corp | GERN | 0.42% | 6.84K | $9.6K |
| 74 | Tyson Foods Inc | TSN | 0.40% | 138 | $9.2K |
| 75 | Techne Corp | TECH | 0.36% | 185 | $8.3K |
| 76 | Rocket Pharmaceuticals Inc | RCKT | 0.34% | 2.31K | $7.9K |
| 77 | Sarepta Therapeutics Inc | SRPT | 0.34% | 419 | $7.8K |
| 78 | Alnylam Pharmaceuticals Inc | ALNY | 0.33% | 26 | $7.6K |
| 79 | QIAGEN N.V. | — | 0.25% | 172 | $5.7K |
| 80 | Pacific Biosciences Of Calif | PACB | 0.22% | 4.22K | $5.1K |
| 81 | US DOLLAR | — | 0.08% | 1.89K | $1.9K |
| 82 | DREYFUS TRSY OBLIG CASH MGMT CL INS | — | 0.04% | 1.03K | $1.0K |
| 83 | EURO | — | 0.00% | 65 | $76.55 |
| 84 | AUSTRALIAN DOLLAR | — | 0.00% | 23 | $17.17 |
| 85 | SWISS FRANC | — | 0.00% | 4 | $5.35 |
| 86 | GREAT BRITISH POUND | — | 0.00% | 2 | $3.86 |
| 87 | DANISH KRONE | — | 0.00% | 18 | $2.96 |
Klik ticker untuk melihat semua ETF yang memilikinya.
Eksposur Sektor
Eksposur Geografis
Bobot negara sebagaimana dilaporkan oleh penyedia data. Label pasar berkembang/maju/frontier mengikuti klasifikasi yang ada di halaman Metodologi. Lindung nilai mata uang: Tidak ada indikasi hedging pada nama dana.
Distribusi
| Yield (TTM) | 3.22% | Dibayarkan (12 bulan terakhir) | $0.7705 |
| Frekuensi | Annual | SEC yield | Tidak disediakan oleh sumber data kami — lihat halaman penerbit |
| Tanggal ex-dividen terakhir | Dec 26, 2025 | Pembayaran terakhir | $0.7705 (Dec 30, 2025) |
| Pertumbuhan 1T | +619.44% | Pertumbuhan 3T / 5T (tahunan) | +128.01% / — |
| Tanggal ex-dividen | Tanggal Pencatatan | Tanggal pembayaran | Jumlah |
|---|---|---|---|
| Dec 26, 2025 | Dec 26, 2025 | Dec 30, 2025 | $0.7705 |
| Dec 26, 2024 | Dec 26, 2024 | Dec 30, 2024 | $0.1071 |
| Dec 22, 2023 | Dec 26, 2023 | Dec 28, 2023 | $0.1350 |
| Dec 23, 2022 | Dec 27, 2022 | Dec 29, 2022 | $0.0650 |
| Dec 27, 2021 | Dec 28, 2021 | Dec 30, 2021 | $0.0250 |
Yield distribusi trailing = total kas 12 bulan terakhir ÷ harga saat ini. Ini BUKAN yield 30 hari SEC dan distribusi tidak dijamin berlanjut. Penjelasan perbedaannya →
Statistik Risiko
| Volatilitas 1T / 3T | 28.00% / 26.43% | Sharpe 1T / 3T | 2.76 / 0.616 |
| Drawdown maks 1T / 3T | -11.71% / -36.66% | Sortino 1T | 4.83 |
| Beta vs S&P 500 (3T) | 1.00 | Korelasi vs S&P 500 (1T) | 0.447 |
| Deviasi sisi bawah 1 tahun | 15.99% | Tingkat bebas risiko yang digunakan | 3.71% (3M T-bill, FRED) |
Dihitung oleh ETF Explorer dari harga penutupan harian yang telah disesuaikan dividen; volatilitas dan drawdown merupakan angka yang disetahunkan/per periode; eksposur S&P 500 diproksikan oleh SPY. Per Aug 27, 2026. Rumus →
Likuiditas
| Volume hari ini | 20.90K | Volume rata-rata | 1.48K |
| AUM | $3.1M | Premium/Diskon | +1.19% |
| Spread bid/ask | Tidak disediakan oleh sumber data kami. Periksa layar kuotasi broker Anda; spread paling lebar pada saat pembukaan dan penutupan. | ||
Premium/discount membandingkan harga pasar tertunda dengan NAV yang terakhir dilaporkan — angka indikatif, bukan premium/discount penutupan resmi. Cara kerja likuiditas ETF →
Aliran Dana (estimasi)
| Periode | Est. arus bersih | % dari AUM awal | AUM awal → akhir |
|---|---|---|---|
| 1 Hari | $0.00 | 0.00% | $3.1M → $3.1M |
| 1 Minggu | $403.7K | +15.59% | $2.6M → $3.1M |
Estimasi ETF Explorer: perubahan AUM yang dilaporkan dikurangi dampak pergerakan pasar, dari snapshot harian kami. Bukan data kreasi/penebusan resmi penerbit.
Sumber Daya Resmi Dana
Tautan eksternal akan membuka situs penerbit atau SEC EDGAR di tab baru. Prospektus dan dokumen resmi selalu menjadi sumber yang berwenang — tinjau sebelum berinvestasi.
Berita Terkini untuk WDNA
Tidak ada artikel yang menyebut dana ini secara langsung dalam 7 hari terakhir — menampilkan liputan ETF umum.
Panduan: AUM adalah ukuran dana. Expense ratio adalah biaya tahunan yang sudah tercermin dalam imbal hasil. NAV adalah nilai aset yang dimiliki dana per unit; harga pasar bisa sedikit di atas (premium) atau di bawah (diskon) NAV. Total return mengasumsikan distribusi diinvestasikan kembali. Setiap dataset menampilkan tanggal datanya masing-masing karena kepemilikan, aset, dan harga diperbarui pada jadwal yang berbeda.